Update date
31 Mar 2019
Shareable Research Card
GRCE - Grace Therapeutics, Inc. Research And Development Expense
This metric view shows GRCE - Grace Therapeutics, Inc. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2018
- Latest reported value
- CA$38,366,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Mar 2019
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2018.
- Latest reported value on this page: CA$38,366,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: CA$38,366,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2018
SEC-backed company facts were refreshed from filings filed on 12 Feb 2026.
Benchmark Context
How Research And Development Expense compares with peers
Grace Therapeutics, Inc. sits in the top quarter of the current research and development expense sample.
Compared with
Compared with 44 companies reporting research and development expense in CAD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 12.8x the current sample midpoint. Research And Development Expense is up about 145% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2016 to 31 Jan 2026.
- Nearby companies in this sample: CAMECO CORP and TECK RESOURCES LTD.
- Current sample position: rank #6 of 44 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Grace Therapeutics, Inc.: Research And Development Expense
Latest period: 2018. Period end: 31 Mar 2019. Units: CAD. Frequency: annual and quarterly.
Research And Development Expense is an SEC-reported metric from company XBRL facts.
Metric Snapshot
- Latest value
- CA$38,366,000
- Coverage range
- 29 Feb 2016 - 31 Mar 2019
- Fact rows
- 5
What This Metric Tells You
- Shows the reported level of research and development expense over 29 Feb 2016 - 31 Mar 2019.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 5 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Grace Therapeutics, Inc. appears at rank #6 in the latest comparison sample.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | BRP Inc. (doo) | CA$434,700,000 | Year - 31 Jan 2026 | Open BRP Inc. Research And Development Expense |
| 2 | CAE INC (cae) | CA$123,200,000 | Year - 31 Mar 2025 | Open CAE INC Research And Development Expense |
| 3 | BCE INC (bce) | CA$60,000,000 | Year - 31 Dec 2025 | Open BCE INC Research And Development Expense |
| 4 | CYBIN INC. (help) | CA$54,910,000 | Year - 31 Mar 2025 | Open CYBIN INC. Research And Development Expense |
| 5 | CAMECO CORP (ccj) | CA$38,467,000 | Year - 31 Dec 2025 | Open CAMECO CORP Research And Development Expense |
| 6 | Grace Therapeutics, Inc. (grce) | CA$38,366,000 | Year - 31 Mar 2019 | Open Grace Therapeutics, Inc. Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Taxonomy
- ifrs-full
- Units tracked
- CAD
- Frequency coverage
- annual and quarterly
- History range
- 29 Feb 2016 - 31 Mar 2019
- Facts on this page
- 5
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Annual (CAD)
Research And Development Expense, YoY Annual Change (%)
Research And Development Expense, Quarterly (CAD)
Grace Therapeutics, Inc. Annual Research And Development Expense (CAD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2018 | CA$38,366,000 | +CA$22,697,000 | +145% | 01 Apr 2018 | 31 Mar 2019 | 20-F | 26 Jun 2019 | 2019 | FY |
| 2017 | CA$15,669,000 | +CA$8,442,000 | +117% | 01 Apr 2017 | 31 Mar 2018 | 20-F | 26 Jun 2019 | 2019 | FY |
| 2016 | CA$7,227,000 | -CA$339,000 | -4.5% | 01 Mar 2016 | 28 Feb 2017 | 20-F | 26 Jun 2019 | 2019 | FY |
| 2015 | CA$7,566,000 | 01 Mar 2015 | 29 Feb 2016 | 20-F | 29 Jun 2018 | 2018 | FY |
Grace Therapeutics, Inc. Quarterly Research And Development Expense (CAD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q1 2017 | CA$426,000 | 31 Mar 2017 | 20-F | 26 Jun 2019 | 2019 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.